aminolevulinic acid has been researched along with Hepatic Porphyria in 20 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a small interfering RNA that is selectively taken up in the liver, both the mechanism and targeted delivery create a complex relationship between givosiran pharmacokinetics (PK) and the pharmacodynamic (PD) response." | 5.91 | Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. ( Lee, J; Melch, M; Robbie, GJ, 2023) |
| " The final model was used to assess the adequacy of the recommended givosiran dosing regimen across demographic and clinical subgroups." | 5.91 | Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. ( Lee, J; Melch, M; Robbie, GJ, 2023) |
| "The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase." | 5.41 | AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023) |
| "The acute hepatic porphyrias (AHPs) are inherited disorders of heme biosynthesis characterized by life-threatening acute neurovisceral attacks precipitated by factors that upregulate hepatic 5-aminolevulinic acid synthase 1 (ALAS1) activity." | 4.31 | RNA interference therapy in acute hepatic porphyrias. ( Balwani, M; Keel, S; Yasuda, M, 2023) |
| "The quantification of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in urine are the first-line tests for diagnosis and monitoring of acute hepatic porphyrias (AHP)." | 4.31 | Quantification of Urine and Plasma Porphyrin Precursors Using LC-MS in Acute Hepatic Porphyrias: Improvement in Routine Diagnosis and in the Monitoring of Kidney Failure Patients. ( Dessendier, N; Gouya, L; Junot, C; Lefebvre, T; Manceau, H; Moulouel, B; Nguyen, AL; Poli, A; Puy, H; Schmitt, C; Talbi, N, 2023) |
| "A new form of acute hepatic porphyria with double genetic defect--deficiency of porphobilinogen deaminase and coproporphyrinogen oxidase--is described." | 3.69 | Coexistence of hereditary coproporphyria with acute intermittent porphyria. ( Gregor, A; Kostrzewska, E; Stachurska, H; Tarczynska-Nosal, S, 1994) |
| "Acute intermittent porphyria is the most common type of AHP, with an estimated prevalence of patients with symptoms of approximately 1 in 100,000." | 3.01 | AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023) |
| "The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase." | 3.01 | AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. ( Balwani, M; Bonkovsky, HL; Lim, JK; Wang, B, 2023) |
| "Acute hepatic porphyrias are inherited metabolic disorders that may present with polyneuropathy, which if not diagnosed early can lead to quadriparesis, respiratory weakness, and death." | 2.72 | Porphyric neuropathy. ( Bonkovsky, HL; Caress, JB; Gandhi Mehta, RK; Rudnick, SR, 2021) |
| " As a small interfering RNA that is selectively taken up in the liver, both the mechanism and targeted delivery create a complex relationship between givosiran pharmacokinetics (PK) and the pharmacodynamic (PD) response." | 1.91 | Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. ( Lee, J; Melch, M; Robbie, GJ, 2023) |
| " The final model was used to assess the adequacy of the recommended givosiran dosing regimen across demographic and clinical subgroups." | 1.91 | Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. ( Lee, J; Melch, M; Robbie, GJ, 2023) |
| "The acute hepatic porphyrias (AHPs) are inherited disorders of heme biosynthesis characterized by life-threatening acute neurovisceral attacks precipitated by factors that upregulate hepatic 5-aminolevulinic acid synthase 1 (ALAS1) activity." | 1.91 | RNA interference therapy in acute hepatic porphyrias. ( Balwani, M; Keel, S; Yasuda, M, 2023) |
| "Patients with acute hepatic porphyria are denied essential operations because of concern that general anaesthesia and surgery will precipitate a life threatening porphyric crisis." | 1.29 | Safety of general anaesthesia and surgery in acute hepatic porphyria. ( Dover, SB; McColl, KE; Moore, MR; Plenderleith, L, 1994) |
| "A new form of acute hepatic porphyria with double genetic defect--deficiency of porphobilinogen deaminase and coproporphyrinogen oxidase--is described." | 1.29 | Coexistence of hereditary coproporphyria with acute intermittent porphyria. ( Gregor, A; Kostrzewska, E; Stachurska, H; Tarczynska-Nosal, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 8 (40.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, B | 1 |
| Bonkovsky, HL | 2 |
| Lim, JK | 1 |
| Balwani, M | 2 |
| Lee, J | 1 |
| Melch, M | 1 |
| Robbie, GJ | 1 |
| Yasuda, M | 1 |
| Keel, S | 1 |
| Poli, A | 1 |
| Manceau, H | 1 |
| Nguyen, AL | 1 |
| Moulouel, B | 1 |
| Dessendier, N | 1 |
| Talbi, N | 1 |
| Puy, H | 1 |
| Junot, C | 1 |
| Gouya, L | 1 |
| Schmitt, C | 1 |
| Lefebvre, T | 1 |
| Gandhi Mehta, RK | 1 |
| Caress, JB | 1 |
| Rudnick, SR | 1 |
| Hift, RJ | 1 |
| Todd, G | 1 |
| Meissner, PN | 1 |
| Kirsch, RE | 1 |
| López Montes, A | 1 |
| Lorenzo, I | 1 |
| Pérez Martínez, J | 1 |
| Bloomer, JR | 1 |
| McGuire, BM | 1 |
| Romeo, G | 1 |
| Böhrer, H | 1 |
| Schmidt, H | 1 |
| Martin, E | 1 |
| Lux, R | 1 |
| Bolsen, K | 1 |
| Goerz, G | 1 |
| Sieg, I | 1 |
| Bhutani, LK | 1 |
| Doss, MO | 3 |
| Gross, U | 2 |
| Honcamp, M | 1 |
| Daume, E | 1 |
| Frank, M | 1 |
| Düsterberg, B | 1 |
| Dover, SB | 1 |
| Plenderleith, L | 1 |
| Moore, MR | 1 |
| McColl, KE | 1 |
| Gregor, A | 1 |
| Kostrzewska, E | 1 |
| Tarczynska-Nosal, S | 1 |
| Stachurska, H | 1 |
| Yano, Y | 1 |
| Kondo, M | 1 |
| Kühnel, A | 1 |
| Schuurmans, MM | 1 |
| Hoffmann, F | 1 |
| Lindberg, RL | 1 |
| Meyer, UA | 1 |
| Hermes-Lima, M | 1 |
| Castilho, RF | 1 |
| Valle, VG | 1 |
| Bechara, EJ | 1 |
| Vercesi, AE | 1 |
| Akagi, R | 1 |
| Prchal, JT | 1 |
| Eberhart, CE | 1 |
| Sassa, S | 1 |
| Rojas, F | 1 |
| Aguilera, S | 1 |
4 reviews available for aminolevulinic acid and Hepatic Porphyria
| Article | Year |
|---|---|
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Topics: Abdominal Pain; Aminolevulinic Acid; Antiemetics; Carcinoma, Hepatocellular; Creatinine; Female; Hem | 2023 |
Porphyric neuropathy.
Topics: Aminolevulinic Acid; Guillain-Barre Syndrome; Humans; Peripheral Nervous System Diseases; Polyneurop | 2021 |
The hepatic porphyrias.
Topics: 5-Aminolevulinate Synthetase; Acute Disease; Adolescent; Adult; Aminolevulinic Acid; Chemical Phenom | 1980 |
[Hereditary coproporphyria (HCP)].
Topics: Aminolevulinic Acid; Biomarkers; Diagnosis, Differential; Mutation; Porphobilinogen; Porphobilinogen | 1998 |
1 trial available for aminolevulinic acid and Hepatic Porphyria
| Article | Year |
|---|---|
Administration of oral activated charcoal in variegate porphyria results in a paradoxical clinical and biochemical deterioration.
Topics: Administration, Oral; Adolescent; Adult; Aminolevulinic Acid; Analysis of Variance; Charcoal; Female | 2003 |
15 other studies available for aminolevulinic acid and Hepatic Porphyria
| Article | Year |
|---|---|
Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
Topics: Adolescent; Adult; Aminolevulinic Acid; Humans; Porphobilinogen Synthase; Porphyrias, Hepatic | 2023 |
RNA interference therapy in acute hepatic porphyrias.
Topics: Aminolevulinic Acid; Heme; Humans; Pain; Porphyrias; Porphyrias, Hepatic; Quality of Life; RNA Inter | 2023 |
Quantification of Urine and Plasma Porphyrin Precursors Using LC-MS in Acute Hepatic Porphyrias: Improvement in Routine Diagnosis and in the Monitoring of Kidney Failure Patients.
Topics: Aminolevulinic Acid; Chromatography, Liquid; Humans; Porphobilinogen; Porphyrias; Porphyrias, Hepati | 2023 |
[Porphyria and inappropriate antidiuretic hormone syndrome].
Topics: Abdominal Pain; Adult; Aminolevulinic Acid; Coproporphyrins; Diuretics; Endometriosis; Female; Furos | 2004 |
Intermittent unexplained abdominal pain: is it porphyria?
Topics: Abdominal Pain; Acute Disease; Adult; Aminolevulinic Acid; Anti-Infective Agents; Cimetidine; Contra | 2007 |
Testing the porphyrinogenicity of propofol in a primed rat model.
Topics: 5-Aminolevulinate Synthetase; Allylisopropylacetamide; Aminolevulinic Acid; Anesthetics, Intravenous | 1995 |
Dual porphyria of coexisting variegata and cutanea tarda.
Topics: Adult; Aged; Aminolevulinic Acid; Feces; Female; Humans; Male; Porphobilinogen; Porphyria Cutanea Ta | 1995 |
Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias.
Topics: Adult; Aminolevulinic Acid; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Copropor | 1995 |
Safety of general anaesthesia and surgery in acute hepatic porphyria.
Topics: Acute Disease; Adult; Aged; Aminolevulinic Acid; Anesthesia, General; Child, Preschool; Contraindica | 1994 |
Coexistence of hereditary coproporphyria with acute intermittent porphyria.
Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Child; Female; Humans; Male; Middle Aged; Pedigree; Po | 1994 |
Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Arginine; Child; Chromatography, Hi | 2000 |
Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria.
Topics: 5-Aminolevulinate Synthetase; Acute Disease; Aminolevulinic Acid; Animals; Arginine; Cytosol; Drug C | 2001 |
Calcium-dependent mitochondrial oxidative damage promoted by 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Calcium; Cell Membrane Permeability; Cell Size; Egtazic Acid; Magnesiu | 1992 |
An acquired acute hepatic porphyria: a novel type of delta-aminolevulinate dehydratase inhibition.
Topics: Acute Disease; Aminolevulinic Acid; Blotting, Western; Colorimetry; Dithiothreitol; Humans; Male; Mi | 1992 |
[Ion-exchange chromatography in the diagnosis of hepatic porphyria].
Topics: Amines; Aminolevulinic Acid; Anion Exchange Resins; Chromatography, Ion Exchange; Humans; Ketones; P | 1974 |